Clinical Trials Logo

Chronic Spontaneous Urticaria clinical trials

View clinical trials related to Chronic Spontaneous Urticaria.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06365879 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair® in patients with refractory chronic spontaneous urticaria

NCT ID: NCT06250400 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

Start date: March 31, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to study patients with chronic spontaneous urticaria. The main question it aims to answer is the efficacy and safety of histamine human immunoglobulin (ShuYangMinNing) in the treatment of chronic spontaneous urticaria.

NCT ID: NCT05992987 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

Assessment of Serum Levels of Adenosine Deaminase and Immunoglobulin E in Patients With Chronic Spontaneous Urticaria

Start date: August 15, 2023
Phase:
Study type: Observational

adenosine deaminase activity (ADA) has been reported to be elevated in various diseases such as psoriasis, acne and juvenile idiopathic arthritis. There is no previous studies that assessed ADA in chronic spontaneous urticaria (CSU) .

NCT ID: NCT05169645 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and Angioedema

STOP CSUA
Start date: February 1, 2022
Phase:
Study type: Observational

Chronic spontaneous urticaria and angioedema (CSUA) is a disease of the skin characterised by hives, swellings or both that last longer than 6 weeks. People with this disease commonly describe poor sleep, reduced quality of life and psychological difficulties such as depression and anxiety. This study seeks to understand relationships between physical activity, sleep and symptoms of urticaria. We are asking individuals with urticaria to wear a fitbit tracker which monitors their physical activity and sleep. Participants also download an app onto their smartphone called Athena CX which is designed by the study team in DCU. The purpose of the app is capture real-time information from participants on mood and any skin symptoms they experience. We will use this information to learn more about possible links between symptoms of urticaria and lifestyle behaviours.

NCT ID: NCT04944602 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria

Start date: July 2021
Phase: Phase 3
Study type: Interventional

• This study is a multicenter, randomized, double-blind, parallel-group, positive-controlled phase III study to evaluate the therapeutic equivalence of SYN008 versus omalizumab for injection (Xolair®) in the treatment of CSU patients who remain symptomatic despite antihistamine treatment.

NCT ID: NCT04893980 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria

Start date: June 16, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a randomized, controlled, single-center clinical study to evaluate the short-term efficacy of low-dose Interleukin-2 injection as an add-on therapy for the treatment of patients aged 18-75 who have been diagnosed with CSU and remain symptomatic despite oral antihistamine treatment .

NCT ID: NCT04404023 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of UB-221 in healthy volunteers.